February 16, 2023
UC San Diego researchers report that a late-stage, pre-clinical small molecule inhibitor reverses malignant hyper-editing by a protein that promotes silencing of the immune response, metastasis and therapeutic resistance in 20 different cancer types.
October 7, 2014
…growth. The findings underscore the emerging recognition that non-coding RNAs help regulate basic cellular processes and may be key to developing new drugs and therapies.
August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
July 12, 2018
…defenses. The study may pave the way to new therapeutic treatments for arenaviruses and hemorrhagic fever.
January 2, 2013
An international team, headed by researchers at the University of California, San Diego School of Medicine, has identified a key enzyme in the reprogramming process that promotes malignant stem cell cloning and the growth of chronic myeloid leukemia (CML), a cancer of the blood and marrow that experts say is…
May 2, 2017
…leading to type 1 and 2 diabetes. Using single-cell RNA sequencing, researchers at University of California San Diego School of Medicine have, for the first time, mapped out pathways that regulate beta cell growth that could be exploited to trick them to regenerate.
December 5, 2017
Using a database of multiple myeloma patient samples and information, researchers at University of California San Diego School of Medicine found that high ADAR1 levels correlate with reduced survival rates. They also determined that blocking the enzyme reduces multiple myeloma regeneration in experimental models derived from patient cancer cells.
March 16, 2023
UC San Diego researchers use a DNA designer drug to restore key protein levels in motor neurons, delaying paralysis in a mouse model of ALS.
June 27, 2016
Researchers at University of California San Diego School of Medicine have found that a likely cause of inflammatory myofibroblastic tumors is deficiency in nonsense-mediated RNA decay (NMD), a system cells use to control which genes are activated.
March 24, 2020
Researchers at four University of California Health medical centers have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients with COVID-19 with remdesivir, a drug that has shown promising activity against multiple viruses.
